Dr. Matthew Alexander Cunningham , MD
Ophthalmology โข Orlando, FL
95 Columbia St
Orlando, FL 328061101
This profile restates public CMS/NPPES data; T-MedInfo gives no medical advice — consult a licensed professional, and call 911 for emergencies.
-
Dr. Matthew Cunningham is listed in NPPES under Ophthalmology.
-
NPI assigned on July 10, 2008; this date does not establish years in practice.
-
Published CMS data list 41,592 Original Medicare Part B services in 2024.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024. Published rows only; this is not a quality measure.
-
Published Part B service records, 2024:
- J2777 โ Injection, faricimab-svoa, 0.1 mg: 21,540 service units.
- J0177 โ Injection, aflibercept hd, 1 mg: 2,720 service units.
- 67028 โ Injection of drug into eye: 2,146 service units.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024. Units differ by code; these are not visits or a measure of quality.
CPTยฎ only copyright 2023 American Medical Association. All rights reserved. Service names are shortened from CPT Consumer Friendly Descriptors (CMS data, 2024). CPT notice
See all 24 records in the table ยท Guide: How to read Medicare Part B data
-
Published CMS data list 1,454 Medicare Part D prescriptions, including refills, in 2024.
Source: CMS, Medicare Part D Prescribers โ by Provider and Drug, 2024. Published rows only; this is not a quality measure.
-
Published Part D records, 2024:
- Prednisolone Acetate โ 331 prescription fills, including refills.
- Neomycin-Polymyxin-Dexameth (Neomycin/Polymyxin B/Dexametha) โ 188 prescription fills, including refills.
- Dorzolamide-Timolol (Dorzolamide Hcl/Timolol Maleat) โ 168 prescription fills, including refills.
Source: CMS, Medicare Part D Prescribers โ by Provider and Drug, 2024. Drug names come from pharmacy claims. Listing a drug here is not an endorsement or a recommendation.
See all 17 records in the table ยท Guide: How to read Medicare Part D prescriber data
-
More Medicare Part B services than 85% of clinicians listed under Ophthalmology in Orlando, FL (2024, 37 clinicians with data). Median for this group: 2,286. Middle half: 1,042 to 15,082.
More Medicare Part B services than 95% of clinicians listed under Ophthalmology in Florida (2024, 1,014 clinicians with data). Median for this group: 2,174. Middle half: 801 to 4,691.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024. Billing and prescribing volume is not a quality rating.
-
Medicare Part B services went from 20,092 in 2020 to 41,592 in 2024.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2020โ2024.
Practice Location & Contact Primary Location
95 Columbia St
Orlando, FL 328061101
Matched by practice address or phone in NPPES. A shared address or phone does not confirm that this clinician works there.
NPPES lists 4 distinct additional practice-address records in Clermont, FL; Lady Lake, FL; Lake Mary, FL and 1 more. See the list
Source: CMS NPPES NPI Registry, practice location records; release date unavailable.
CMS Doctors and Clinicians lists 1 group name: Retina Vitreous Consultants. See the list
Source: CMS Doctors and Clinicians National Downloadable File, release date unavailable.
Listings do not confirm current availability, employment or a shared ownership network.
Medicare Profile & Education
Source: CMS Doctors and Clinicians National Downloadable File
University Of Florida College Of Medicine
2007
What Public CMS Data Show
Ophthalmology: NPPES taxonomy is a reported classification, not proof of board certification.
Medicare patients
1,653 people with Original Medicare in 2024
It gives a sense of how many people with Medicare this clinician treated that year.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider, 2024.
Medicare-allowed amount
About $5,017,137 in 2024
The total amount Medicare approved for these services in 2024. It includes what Medicare paid and what patients or their other insurance owed, such as the deductible and coinsurance.
It shows the total cost of this clinician's Original Medicare services under Medicare's fee rules.
What this does not show: Medicare-allowed amount
This is not the clinician's income. Part of it can go to a clinic or group practice, staff, equipment or drugs. It is not the price you will pay.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024.
Paid by Medicare
About $3,934,927 in 2024
The part of the Medicare-allowed amount that Medicare itself paid in 2024, after patients' deductibles and coinsurance.
The gap between the allowed amount and this number is roughly what patients and their other insurance paid.
What this does not show: Paid by Medicare
This is not the clinician's income and not a measure of quality.
Source: CMS, Medicare Physician & Other Practitioners โ by Provider and Service, 2024.
30-day fills
2,449 standardized 30-day fills in 2024
CMS converts prescriptions to 30-day supplies so they can be compared. A 90-day prescription counts as about three 30-day fills.
What this does not show: 30-day fills
It is not a count of patients and not a measure of quality.
Part D drug cost
$347,349 in 2024
The total cost of these prescriptions in 2024, paid by Medicare drug plans, patients and other payers together.
It shows the total spending on drugs this clinician prescribed, not what any one patient paid.
What this does not show: Part D drug cost
A higher cost often reflects the type of medicines a specialty uses. It is not your out-of-pocket cost and not a measure of quality.
Source: CMS, Medicare Part D Prescribers โ by Provider and Drug, 2024.
Open Payments general payments, program year 2025
All general payments: $78,505.14 across 72 records.
By nature of payment (3 largest of 6)
- Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program: $27,202.41 across 7 records.
- Consulting Fee: $25,655.00 across 7 records.
- Compensation for serving as faculty or as a speaker for a medical education program: $15,771.00 across 4 records.
Reporting-company totals (3 largest of 10)
- Genentech, Inc.: $18,891.83 across 5 records.
- Apellis Pharmaceuticals, Inc.: $18,042.63 across 13 records.
- Regeneron Pharmaceuticals, Inc.: $17,702.15 across 13 records.
Research and ownership records are not included in these totals; they are in the table below.
A reported payment does not necessarily mean the financial relationship is improper and is not a measure of care quality. Clinicians can review and dispute these records.
Source: Calculated by T-MedInfo from CMS Open Payments general-payment records for program year 2025 (published June 30, 2026).
Years since graduation
19 years (graduated 2007)
CMS Doctors and Clinicians data list 2007 as the year this clinician finished professional school.
It tells you roughly how long ago the clinician finished school.
What this does not show: Years since graduation
It is not the number of years in practice, and more years does not mean better care.
Source: CMS Doctors and Clinicians National Downloadable File.
NPI first issued
2008
The year this clinician's National Provider Identifier (NPI) was issued. An NPI is a unique 10-digit ID that US health care providers use for billing.
What this does not show: NPI first issued
NPIs have been issued only since 2005, so this year is not necessarily when the clinician started practicing.
Source: CMS NPPES NPI Registry.
Accepts Medicare assignment
CMS data list this clinician as accepting Medicare assignment. This means agreeing to take the Medicare-approved amount as full payment for covered services.
With Original Medicare, you usually pay only your deductible and coinsurance, and the office sends the claim to Medicare for you.
Medicare assignment applies to Original Medicare. It does not tell you whether the clinician is in a Medicare Advantage plan's network, accepts other insurance, or is taking new patients.
Source: CMS Doctors and Clinicians; Medicare.gov, โDoes your provider accept Medicare as full payment?โ
No telehealth indicator
CMS shows this indicator only when recent Medicare claims include telehealth services. The clinician may still offer telehealth; ask the office.
Source: CMS, Telehealth Indicator on Medicare Care Compare (fact sheet, January 2023); CMS Doctors and Clinicians.
Enrolled in Medicare (PECOS)
Dr. Cunningham has a Medicare enrollment record in PECOS, the CMS system clinicians use to enroll so they can bill Medicare or order services for people with Medicare.
It does not show whether the clinician accepts assignment, is in your plan's network, or is taking new patients.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Can order Medicare-covered services
CMS lists Dr. Cunningham as eligible to order or refer Medicare Part B clinical laboratory and imaging services, durable medical equipment (DME) and home health services for people with Medicare.
Medicare pays for these items and services only when they are ordered by an eligible clinician.
What this does not show: Can order Medicare-covered services
It does not mean the clinician offers these services directly.
Source: CMS Medicare Fee-For-Service Public Provider Enrollment (PECOS); CMS Order and Referring file.
Compared with the same specialty in Orlando and Florida
Billing and prescribing volume is not a quality rating.
Medicare Part B services
More Medicare Part B services than 85% of clinicians listed under Ophthalmology in Orlando, FL (2024, 37 clinicians with data). Median for this group: 2,286. Middle half: 1,042 to 15,082.
More Medicare Part B services than 95% of clinicians listed under Ophthalmology in Florida (2024, 1,014 clinicians with data). Median for this group: 2,174. Middle half: 801 to 4,691.
Medicare-allowed amount
A higher Medicare-allowed amount than 90% of clinicians listed under Ophthalmology in Orlando, FL (2024, 37 clinicians with data). Median for this group: $254,197. Middle half: $117,415 to $1,821,598.
A higher Medicare-allowed amount than 95% of clinicians listed under Ophthalmology in Florida (2024, 1,014 clinicians with data). Median for this group: $239,067. Middle half: $86,567 to $537,508.
Paid by Medicare
A higher Medicare payment amount than 90% of clinicians listed under Ophthalmology in Orlando, FL (2024, 37 clinicians with data). Median for this group: $186,104. Middle half: $85,990 to $1,435,810.
A higher Medicare payment amount than 95% of clinicians listed under Ophthalmology in Florida (2024, 1,014 clinicians with data). Median for this group: $175,260. Middle half: $61,464 to $390,296.
Medicare Part D prescriptions
More Part D prescriptions than 70% of clinicians listed under Ophthalmology in Orlando, FL (2024, 38 clinicians with data). Median for this group: 755. Middle half: 356 to 1,802.
Close to the middle for clinicians listed under Ophthalmology in Florida (2024, 1,099 clinicians with data). Median for this group: 1,203. Middle half: 442 to 2,490.
Part D drug cost
A higher Part D drug cost than 70% of clinicians listed under Ophthalmology in Orlando, FL (2024, 38 clinicians with data). Median for this group: $152,032. Middle half: $14,840 to $433,329.
A higher Part D drug cost than 75% of clinicians listed under Ophthalmology in Florida (2024, 1,099 clinicians with data). Median for this group: $114,958. Middle half: $23,858 to $310,282.
52 active clinicians are listed under Ophthalmology with a practice address in Orlando, FL (1,582 in Florida).
Addresses are self-reported to NPPES and may be out of date.
Telehealth indicator in Orlando
0% of these 52 clinicians have the CMS telehealth indicator.
71.2% of these 52 clinicians are listed by CMS as accepting Medicare assignment.
CMS data by year
Changes may reflect reporting, coverage or privacy limits, not changes in care quality.
-
Medicare Part B services
Medicare Part B services increased 107% from 20,092 in 2020 to 41,592 in 2024.
- 2020: 20,092
- 2021: 19,171
- 2022: 20,113
- 2023: 36,136
- 2024: 41,592
-
Medicare-allowed amount
Medicare-allowed amount stayed about the same: $5,016,618 in 2020 and $5,017,137 in 2024.
- 2020: $5,016,618
- 2021: $4,801,337
- 2022: $4,637,824
- 2023: $5,162,063
- 2024: $5,017,137
-
Paid by Medicare
Paid by Medicare stayed about the same: $3,940,062 in 2020 and $3,934,927 in 2024.
- 2020: $3,940,062
- 2021: $3,776,953
- 2022: $3,639,821
- 2023: $4,046,168
- 2024: $3,934,927
-
Medicare Part D prescriptions
Medicare Part D prescriptions stayed about the same: 1,433 in 2020 and 1,454 in 2024.
- 2020: 1,433
- 2021: 1,463
- 2022: 1,311
- 2023: 1,477
- 2024: 1,454
-
30-day fills
30-day fills increased 21% from 2,027 in 2020 to 2,449 in 2024.
- 2020: 2,027
- 2021: 2,216
- 2022: 2,193
- 2023: 2,482
- 2024: 2,449
-
Part D drug cost
Part D drug cost increased 15% from $301,368 in 2020 to $347,349 in 2024.
- 2020: $301,368
- 2021: $257,268
- 2022: $261,174
- 2023: $339,824
- 2024: $347,349
-
Industry payments (Open Payments)
Industry payments (Open Payments) increased 1143% from $6,983.33 in 2021 to $86,787.59 in 2025.
- 2021: $6,983.33
- 2022: $43,790.66
- 2023: $148,731.91
- 2024: $122,291.01
- 2025: $86,787.59
Sources: CMS Medicare Physician & Other Practitioners (2024), CMS Medicare Part D Prescribers (2024), CMS Open Payments (2025), CMS Doctors and Clinicians, CMS NPPES NPI Registry. Specialty names follow the NUCC Health Care Provider Taxonomy.
Text: T-MedInfo ยท Report an error.
Pharma & Medical Device Financial Disclosures
Payments and other transfers of value that drug and medical device companies reported to CMS Open Payments
Program year 2025 (payments made January 1 โ December 31, 2025): 76 records totaling $86,787.59.
| Manufacturer | Payment Nature | Product | Type | Amount ($) |
|---|---|---|---|---|
| Genentech, Inc. |
Consulting Fee
Cash or cash equivalent
|
โ | General | $18,500.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $8,041.00 |
| Genentech, Inc. |
General
In-kind items and services
|
โ | Research | $6,502.00 |
| Astellas Pharma US Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
Izervay | General | $6,000.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $5,640.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $5,640.00 |
| Astellas Pharma US Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
Izervay | General | $5,000.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $4,730.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $2,308.74 |
| ANI Pharmaceuticals, Inc. |
Honoraria
Cash or cash equivalent
|
ILUVIEN | General | $2,025.00 |
| Alcon Research LLC |
Consulting Fee
Cash or cash equivalent
|
UNITY | General | $1,860.00 |
| Regeneron Pharmaceuticals, Inc. |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
EYLEA HD | General | $1,613.67 |
| Ocular Therapeutix, Inc. |
Consulting Fee
Cash or cash equivalent
|
โ | General | $1,600.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $1,500.00 |
| Apellis Pharmaceuticals, Inc. |
Compensation for serving as faculty or as a speaker for a medical education program
Cash or cash equivalent
|
Syfovre | General | $1,500.00 |
| Alcon Vision LLC |
Consulting Fee
Cash or cash equivalent
|
UNITY | General | $1,395.00 |
| Astellas Pharma US Inc |
Travel and Lodging
Cash or cash equivalent
|
Izervay | General | $1,101.41 |
| Regeneron Pharmaceuticals, Inc. |
Travel and Lodging
In-kind items and services
|
EYLEA HD | General | $1,055.00 |
| Alcon Vision LLC |
Consulting Fee
Cash or cash equivalent
|
โ | General | $1,000.00 |
| Astellas Pharma US Inc |
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program
Cash or cash equivalent
|
Izervay | General | $1,000.00 |
| Regeneron Pharmaceuticals, Inc. |
Travel and Lodging
In-kind items and services
|
EYLEA HD | General | $994.86 |
| Ocular Therapeutix, Inc. |
Consulting Fee
Cash or cash equivalent
|
โ | General | $800.00 |
| Genentech, Inc. |
General
In-kind items and services
|
โ | Research | $607.27 |
| Genentech, Inc. |
General
In-kind items and services
|
โ | Research | $607.27 |
| Genentech, Inc. |
General
In-kind items and services
|
Vabysmo | Research | $565.91 |
(top 25 shown)
Source: CMS Open Payments, program year 2025, released June 30, 2026.
Performed Procedures & Service Volume
CPTยฎ is a registered trademark of the American Medical Association. CPT codes, descriptions and other data only are copyright 2016โ2023 American Medical Association. All rights reserved. Applicable FARS/HHSARS apply. Descriptions of CPT codes are the AMA's CPT Consumer Friendly Descriptors as published by CMS in the Medicare Physician & Other Practitioners โ by Provider and Service data, 2017โ2024; they are plain-language summaries, not for clinical coding or documentation. HCPCS Level II codes and descriptions are from CMS. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
| HCPCS Code | Services | Patients | Submitted Charge | Medicare Allowed |
|---|---|---|---|---|
|
J2777
Injection, faricimab-svoa, 0.1 mg
|
21,540 | 83 | $100.00 | $34.58 |
|
J0177
Injection, aflibercept hd, 1 mg
|
2,720 | 115 | $1318.75 | $328.26 |
|
67028
Injection of drug into eye
|
2,146 | 538 | $804.24 | $116.70 |
|
Q5128
Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg
|
1,855 | 77 | $1200.00 | $230.75 |
|
J2781
Injection, pegcetacoplan, intravitreal, 1 mg
|
1,800 | 23 | $681.75 | $147.15 |
|
J0178
Injection, aflibercept, 1 mg
|
1,774 | 227 | $2381.06 | $822.96 |
|
92134
Imaging of retina
|
1,660 | 696 | $110.00 | $38.39 |
|
92250
Photography of the retina
|
1,579 | 1,390 | $126.00 | $35.07 |
|
J3490
Unclassified drugs
|
1,116 | 76 | $992.47 | $265.00 |
|
99426
Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month
|
1,113 | 243 | $200.00 | $60.71 |
|
J2782
Injection, avacincaptad pegol, 0.1 mg
|
1,040 | 12 | $525.00 | $108.66 |
|
92014
Established patient complete exam of visual system
|
854 | 790 | $339.84 | $119.52 |
|
99213
Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
|
736 | 574 | $250.00 | $88.17 |
|
99427
Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month
|
387 | 194 | $150.00 | $46.06 |
|
J2778
Injection, ranibizumab, 0.1 mg
|
345 | 21 | $740.00 | $161.69 |
|
J7312
Injection, dexamethasone, intravitreal implant, 0.1 mg
|
217 | 16 | $494.60 | $189.33 |
|
99214
Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
|
158 | 149 | $350.00 | $124.92 |
|
92004
New patient complete exam of visual system
|
141 | 141 | $398.91 | $141.77 |
|
99204
New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
|
129 | 129 | $500.00 | $163.75 |
|
J7999
Compounded drug, not otherwise classified
|
113 | 38 | $400.00 | $83.74 |
|
92235
Exam of retinal blood vessels using a special camera after injection of a dye
|
81 | 79 | $397.88 | $150.01 |
|
76512
2d ultrasound scan of eye tissue and structures
|
40 | 30 | $219.00 | $45.63 |
|
99203
New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
|
33 | 33 | $310.00 | $109.03 |
|
67036
Removal of eye fluid (vitreous) between lens and retina
|
15 | 14 | $4000.00 | $744.87 |
Source: CMS Part B by Provider and Service, 2024; services under 11 beneficiaries omitted by CMS. Privacy limits
Submitted charges are billed amounts, not a price quote for your visit.
Medicare Part D Prescribing Profile & Medications
Medicare Part D prescriptions filled, including refills, in 2024.
| Brand Name | Generic Name | Prescriptions | Day Supply | Total Cost | Patients |
|---|---|---|---|---|---|
| Prednisolone Acetate | Prednisolone Acetate | 331 | 15,514 | $13,426.03 | 178 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 188 | 4,256 | $2,118.93 | 134 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 168 | 13,069 | $1,873.88 | 74 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 161 | 7,388 | $3,970.75 | 56 |
| Latanoprost | Latanoprost | 136 | 8,735 | $1,639.30 | 45 |
| Brimonidine Tartrate | Brimonidine Tartrate | 108 | 5,712 | $1,864.60 | 39 |
| Eylea | Aflibercept | 106 | 2,968 | $231,256.48 | 26 |
| Timolol Maleate | Timolol Maleate | 62 | 4,272 | $347.33 | 27 |
| Dorzolamide Hcl | Dorzolamide Hcl | 32 | 2,276 | $552.28 | 12 |
| Atropine Sulfate | Atropine Sulfate | 27 | 1,078 | $848.64 | 17 |
| Prednisone | Prednisone | 24 | 669 | $134.77 | โ |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 23 | 1,112 | $1,571.98 | โ |
| Syfovre | Pegcetacoplan/Pf | 23 | 590 | $50,370.00 | โ |
| Combigan | Brimonidine Tartrate/Timolol | 21 | 918 | $8,731.83 | โ |
| Travoprost | Travoprost | 18 | 767 | $3,371.24 | โ |
| Difluprednate | Difluprednate | 14 | 565 | $1,870.92 | โ |
| Lucentis | Ranibizumab | 12 | 336 | $23,400.00 | โ |
Source: CMS Part D by Provider and Drug, 2024; rows below 11 claims omitted by CMS; volume isn’t quality. Privacy limits
Specialties & License Numbers Reported to NPPES
Self-certified to NPPES: 2023-04-20NUCC Taxonomy Code: 207W00000X
An ophthalmologist has the knowledge and professional skills needed to provide comprehensive eye and vision care. Ophthalmologists are medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, an ophthalmologist prescribes vision services, including glasses and contact lenses.
NUCC Taxonomy Code: 207WX0107X
An ophthalmologist who specializes in the diagnosis and treatment of vitreoretinal diseases.
Additional State Medicaid & Healthcare Payer Identifiers
Medicare (PECOS) Enrollment & Ordering Eligibility
Source: CMS PECOSPRACTITIONER - OPHTHALMOLOGY
I20130521000592
FL
1254519614
Sources: CMS Provider Enrollment and Order and Referring. Medicare enrollment is a billing status, not an accreditation or quality rating.
Medicare Group Practice Enrollments
Source: CMS Doctors and Clinicians National Downloadable File
Retina Vitreous Consultants
95 Columbia St, Orlando, FL 328061101
Phone: 4078499621
Secondary Practice Locations
4880 N Highway 19a Ste 100
Mount Dora, FL 327572018
Phone: 3523571203
2270 E Highway 50
Clermont, FL 347116052
Phone: 3523430716
790 South Highway 27 / 441
Lady Lake, FL 321594540
Phone: 3522599944
1025 Primera Blvd
Lake Mary, FL 327462175
Phone: 4073331570
Clinicians Sharing This Practice Address or Phone
Clinicians sharing this NPPES address, phone or fax; a shared contact does not mean they work together.
Ophthalmology
Doctor of Medicine (M.D.)
Ophthalmology
Doctor of Medicine (M.D.)
Ophthalmology
Doctor of Medicine (M.D.)
Ophthalmology
Doctor of Medicine (M.D.)
Ophthalmology
Doctor of Medicine (M.D.)
Ophthalmology
Doctor of Medicine (M.D.)
Career & Practice History Timeline
Changes recorded in monthly NPPES data files: addresses, names, credentials, specialties and NPI status
Registered at 95 COLUMBIA ST, ORLANDO, FL 328061101 (Tel: 4078499621)
Ophthalmology (license number reported to NPPES: FL ME114768)
NPI status registered as active in NPPES database
Registered at 1025 PRIMERA BLVD, LAKE MARY, FL 327462175 (Tel: 4073331570)
Registered at 8786 PERIMETER PARK BLVD, JACKSONVILLE, FL 322166347 (Tel: 9049979202)
Recorded as MATTHEW CUNNINGHAM, MD
Ophthalmology (license number reported to NPPES: FL ME114768)
NPI status registered as active in NPPES database
Registered at 1025 PRIMERA BLVD, LAKE MARY, FL 327462175 (Tel: 4073331570)
Registered at 8786 PERIMETER PARK BLVD, JACKSONVILLE, FL 322166347 (Tel: 9049979202)
Recorded as MATTHEW CUNNINGHAM, MD
Ophthalmology (license number reported to NPPES: FL ME114768)
First registered as active Individual Practitioner in NPPES Database.
NPI Administrative Meta
Other Ophthalmology Specialists in Orlando
- Dr. John Randolph, MD
- Dr. Elliot Cooperman, MD
- Dr. Margaret Poulos, MD
- Dr. John Olson, MD
- Dr. Robert Kraut, MD
- Dr. Mehul Patel, MD
Mailing Address
8786 Perimeter Park Blvd
Jacksonville, FL 322166347
Phone: 9049979202